Table 1 Clinical characteristics of the neo-adjuvant cohort
From: Dual roles for immune metagenes in breast cancer prognosis and therapy prediction
Characteristic | MDACC-701 | Â |
|---|---|---|
| Â | Number | Percentage |
Age at diagnosis, years | Â | Â |
 40 | 134 | 19 |
 41-50 | 247 | 35 |
 >50 | 320 | 46 |
Chemotherapy type | Â | Â |
 FAC | 74 | 11 |
 FAC + paclitaxel | 236 | 34 |
 FAC + docetaxel | 61 | 9 |
 FEC | 33 | 5 |
 FEC + paclitaxel | 73 | 10 |
 Paclitaxel | 65 | 9 |
 Docetaxel | 39 | 6 |
 Unspecified | 120 | 17 |
Chemotherapy response | Â | Â |
 pCR or RCB 0,1 | 188 | 27 |
 No pCR or RCB 2,3 | 492 | 70 |
 Unspecified | 21 | 3 |
Estrogen receptor status | Â | Â |
 Positive | 385 | 55 |
 Negative | 300 | 43 |
 Unspecified | 16 | 2 |
HER2/neu status | Â | Â |
 Positive | 65 | 9 |
 Negative | 561 | 80 |
 Unspecified | 75 | 11 |
Intrinsic subtypes | Â | Â |
 Basal | 211 | 30 |
 LumA | 216 | 31 |
 LumB | 135 | 19 |
 HER2-E | 74 | 11 |
 Claudin-low | 47 | 7 |
 Normal-like | 16 | 2 |
 Unspecified | 2 | 0.3 |